Thera-SAbDab

TEPROTUMUMAB

>   Structural Summary
TherapeuticTeprotumumab
TargetIGF1R
Heavy ChainQVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPPWTFGQGTKVESK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Preregistration
Estimated Status (June '19)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedGenmab, Roche, Horizon Therapeutics plc
Conditions Approvedna
Conditions ActiveGraves ophthalmopathy
Conditions DiscontinuedDiabetic macular oedema, Advanced breast cancer, Hodgkin's disease, Non-Hodgkin's lymphoma, Non-small cell lung cancer, Sarcoma, Solid tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]